We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+57.75%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.48B
AUM Growth
+$1.48B
Cap. Flow
+$437M
Cap. Flow %
9.75%
Top 10 Hldgs %
48.38%
Holding
120
New
23
Increased
28
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$58.3M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$55.9M
3
AXSM icon
Axsome Therapeutics
AXSM
+$37.2M
4
SYRE icon
Spyre Therapeutics
SYRE
+$34.8M
5
ABBV icon
AbbVie
ABBV
+$34.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$74M
2
IMVT icon
Immunovant
IMVT
+$54.7M
3
ROIV icon
Roivant Sciences
ROIV
+$44.6M
4
HRMY icon
Harmony Biosciences
HRMY
+$32.6M
5
RLAY icon
Relay Therapeutics
RLAY
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERE
1
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$465M 10.38%
10,965,193
+876,808
+9% +$25.2M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$398M 8.89%
28,057,456
+364,539
+1% +$4.14M
LIAN
3
DELISTED
LianBio American Depositary Shares
LIAN
$257M 5.74%
57,558,451
– –
ACLX
4
DELISTED
Arcellx
ACLX
$252M 5.63%
4,544,809
+578,831
+15% +$26.1M
NUVL
5
DELISTED
Nuvalent
NUVL
$215M 4.79%
2,917,991
+454,540
+18% +$28.1M
INBX
6
DELISTED
Inhibrx, Inc. Common Stock
INBX
$162M 3.61%
4,256,104
– –
SLNO
7
DELISTED
Soleno Therapeutics
SLNO
$124M 2.76%
3,074,542
– –
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.36B
$99M 2.21%
2,154,110
+1,773,282
+466% +$55.9M
IMVT icon
9
Immunovant
IMVT
$7.86B
$98.1M 2.19%
2,328,082
-1,486,609
-39% -$54.7M
IOVA icon
10
Iovance Biotherapeutics
IOVA
$2.04B
$97.4M 2.17%
11,979,415
+16,477
+0.1% +$86.2K
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$95.1M 2.12%
4,024,400
-18,791
-0.5% -$335K
AXSM icon
12
Axsome Therapeutics
AXSM
$11.9B
$82.6M 1.84%
1,038,019
+556,370
+116% +$37.2M
MDT icon
13
Medtronic
MDT
$113B
$80.5M 1.8%
976,652
+389,652
+66% +$29.7M
CRGX
14
DELISTED
CARGO Therapeutics
CRGX
$79.6M 1.78%
+3,436,600
New +$58.3M
MGTX icon
15
MeiraGTx Holdings
MGTX
$1.08B
$79.5M 1.78%
11,331,103
– –
VRNA
16
DELISTED
Verona Pharma
VRNA
$76.9M 1.72%
3,866,214
-140,983
-4% -$2.08M
BHVN icon
17
Biohaven
BHVN
$2.04B
$73.8M 1.65%
1,725,047
+973,227
+129% +$30.3M
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
$71.4M 1.59%
1,957,246
+436,830
+29% +$11.4M
BBIO icon
19
BridgeBio Pharma
BBIO
$16.6B
$70.6M 1.58%
1,748,933
– –
PCVX icon
20
Vaxcyte
PCVX
$7.71B
$68.4M 1.53%
1,088,486
-254,265
-19% -$13.2M
LYRA
21
DELISTED
LYRA THERAPEUTICS INC
LYRA
$66.8M 1.49%
255,151
– –
IRON icon
22
Disc Medicine
IRON
$2.82B
$59.1M 1.32%
1,023,045
+127,404
+14% +$6.52M
SYRE icon
23
Spyre Therapeutics
SYRE
$8.34B
$56.1M 1.25%
2,606,679
+2,525,563
+3,114% +$34.8M
NTRA icon
24
Natera
NTRA
$36.4B
$53.3M 1.19%
850,225
+632,047
+290% +$31.6M
RAPT
25
DELISTED
RAPT Therapeutics
RAPT
$53.2M 1.19%
267,494
+27,412
+11% +$3.39M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Perceptive Advisors held 120 positions worth $4.48B, up 49% from $3B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $437M of net new capital in Q4 2023, opening 23 new positions and adding to 28 existing holdings. Its largest new stake was CARGO Therapeutics: 3,436,600 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Immunovant, an estimated $54.7M trimmed.

  • Perceptive Advisors's largest Q4 2023 buy was CARGO Therapeutics: 3,436,600 shares worth $79.6M.
  • Perceptive Advisors added most to Rhythm Pharmaceuticals in Q4 2023, an estimated $55.9M increase.
  • Perceptive Advisors's biggest Q4 2023 reduction was Immunovant, cutting an estimated $54.7M.
  • Perceptive Advisors fully exited argenx in Q4 2023, selling an estimated $74M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $4.48B portfolio in Q4 2023.
  • Perceptive Advisors opened 23 new positions and closed 19 in Q4 2023.
  • Perceptive Advisors's portfolio value rose 49% quarter-over-quarter to $4.48B.

Based on Perceptive Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.